Health status of Asian Americans

Seasoned Leader Jim Kean Takes the Helm as CEO of Molecular You for US Expansion

Retrieved on: 
Tuesday, July 18, 2023

Kean, a highly accomplished leader and long-time advisor to Molecular You, brings a wealth of experience and a passion for transforming the future of personalized healthcare.

Key Points: 
  • Kean, a highly accomplished leader and long-time advisor to Molecular You, brings a wealth of experience and a passion for transforming the future of personalized healthcare.
  • The company's expansion into the US market under Jim Kean's leadership marks a significant milestone in its mission to reshape the landscape of healthcare.
  • "Jim Kean's extensive experience and visionary leadership make him the ideal choice to lead Molecular You's expansion in the United States," said Dr.
  • "I am honored to join Molecular You at this pivotal moment and lead its US expansion," said Jim Kean, newly appointed CEO of Molecular You.

Global Healthcare Mobility Solutions Market Report 2023: Increasing Digitalization and Increasing use of Smart Devices in Healthcare Drives Growth

Retrieved on: 
Monday, July 17, 2023

DUBLIN, July 17, 2023 /PRNewswire/ -- The "Healthcare Mobility Solutions Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 17, 2023 /PRNewswire/ -- The "Healthcare Mobility Solutions Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The increasing digitalization and increasing use of smart devices in healthcare are expected to propel the growth of the healthcare mobility solutions market going forward.
  • Global Healthcare Mobility Solutions Market, Segmentation By Product type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
    6.2.
  • Global Healthcare Mobility Solutions Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Retrieved on: 
Monday, July 17, 2023

This open-label, single-center, investigator-initiated study was conducted at the Bateman Horne Center (“BHC”) with an unrestricted investigational grant.

Key Points: 
  • This open-label, single-center, investigator-initiated study was conducted at the Bateman Horne Center (“BHC”) with an unrestricted investigational grant.
  • Treatment with Val/Cel was generally well tolerated, with an observed safety profile consistent with the known safety profiles of valacyclovir and celecoxib.
  • There were no serious adverse events observed in this study and only one treated patient discontinued treatment due to adverse events, possibly related to Val/Cel treatment.
  • “We look forward to engaging the Food and Drug Administration to discuss progressing this novel treatment option into active Phase 2 clinical development.”

NeaChat Launches GPT-4-Based Personalized Healthy Eating Assistant "What to Eat?"

Retrieved on: 
Wednesday, July 12, 2023

Whether users are crafting individual plans or managing the dietary health of a family, "What to Eat?"

Key Points: 
  • Whether users are crafting individual plans or managing the dietary health of a family, "What to Eat?"
  • features and capabilities include:
    Personal Information-Based Customization: Users need only to provide basic personal information, such as age, sex, height, and weight, and NeaChat will use this information to customize a healthy diet plan.
  • Whether users are aiming to maintain health, lose weight, or build muscle, NeaChat can develop an appropriate diet plan to achieve goals.
  • aims to provide users with personalized, scientifically reasonable diet plans to promote a healthy lifestyle and balanced nutrition.

Quest Launches Consumer-Initiated Genetic Test on questhealth.com to Deliver Personalized, Actionable Health Risk Insights

Retrieved on: 
Tuesday, July 11, 2023

SECAUCUS, N.J., July 11, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the launch of its first consumer-initiated genetic test, now exclusively available through the company's consumer health business at questhealth.com. Called Genetic Insights, the new offering helps people understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counseling.

Key Points: 
  • Called Genetic Insights , the new offering helps people understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counseling.
  • "Genetic Insights goes beyond the typical consumer genetic test.
  • Based on the results of this test and personal or family health history, an individual's physician may suggest additional genetic testing.
  • The Genetics Insights test does not identify genetic risk markers of all known inheritable diseases.

Huawei Unveils Three Innovative Data Center Facility Solutions at 2023 Global Smart Green Data Center Summit

Retrieved on: 
Tuesday, July 4, 2023

ULANQAB, China, July 4, 2023 /PRNewswire/ -- The 2023 Global Smart Green Data Center Summit took place on July 4th in Ulanqab, Inner Mongolia.

Key Points: 
  • ULANQAB, China, July 4, 2023 /PRNewswire/ -- The 2023 Global Smart Green Data Center Summit took place on July 4th in Ulanqab, Inner Mongolia.
  • One highlight of the event was the unveiling of Huawei's three innovative data center facility solutions.
  • Fei Zhenfu, President of Huawei Data Center Facility Domain, unveiled the next-generation indirect evaporative cooling solution EHU and the mobile intelligent management solution iManager-M.
  • These scenario-based data center solutions promise optimal reliability throughout the lifecycle and aim to drive the high-quality development of the data center industry.

EPI’s Alpha-Stim AID Offered for First Time in the UK’s NHS Primary Care

Retrieved on: 
Thursday, June 29, 2023

“Antidepressants and talk therapy treatments aren’t always acceptable or effective for everyone, and Alpha-Stim AID offers an additional therapeutic option.

Key Points: 
  • “Antidepressants and talk therapy treatments aren’t always acceptable or effective for everyone, and Alpha-Stim AID offers an additional therapeutic option.
  • The Alpha-Stim AID is a non-drug cranial electrotherapy stimulation (CES) device that is CE marked and U.S. FDA cleared to safely and effectively treat anxiety.
  • The use of Alpha-Stim AID in Northamptonshire is expected to be a catalyst for widespread use throughout the rest of the United Kingdom.
  • “The positive results and feedback from the people who used Alpha-Stim AID during the research project surpassed my expectations.

Pain Management Issues in Potentially Vulnerable Patient Populations ― Clinical Research, Legislative Actions, and Educational Programs Moving Forward

Retrieved on: 
Wednesday, June 28, 2023

FAIRFIELD, N.J., June 28, 2023 /PRNewswire/ -- Pain Insights conducted a patient-centered survey to better understand the needs of patients with recurrent and chronic pain, review pain management needs in potentially vulnerable patient populations across the lifespan, such as Veterans, the elderly, unborn children, and those with genetic diseases, and to present information on potential pain-related initiatives. 

Key Points: 
  • Pain Insights, Inc. announces a comprehensive market research study conducted among 1,147 sufferers of recurrent and chronic pain.
  • Reactions were also obtained to changes that could be made in updates to the 2016 CDC "Guideline for Prescribing Opioids for Chronic Pain."
  • The internet-based survey was completed in September 2022 by 1,147 patients suffering from recurrent or chronic pain.
  • - The findings will lend insights into: patient engagement activities, patient-reported outcomes (PROs), pain in vulnerable populations, new product development, educational initiatives, legislative actions, and strategic planning strategies.

EQS-News: Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

Retrieved on: 
Wednesday, June 28, 2023

Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN

Key Points: 
  • Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN
    “We are excited to inform the specialist audience about the first successful procedure with our Epygon system,” said Dr. Christophe Giot, Vice President Clinical Affairs.
  • “Our device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and physiological blood flow.
  • The objective of the study is to evaluate the safety and efficacy of Epygon valve implantation at 30 days.
  • Affluent Medical anticipates presenting interim results from the first five patients of the Minerva pilot study at the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in October 2023.

Navina Unveils First-of-Its-Kind Generative AI Assistant for Primary Care Providers

Retrieved on: 
Tuesday, June 27, 2023

NEW YORK, June 27, 2023 /PRNewswire/ -- Navina, the Artificial Intelligence (AI)-powered platform that transforms large amounts of patient data into actionable insights at the point of care, today announced the development of its proprietary AI assistant, which leverages the most advanced generative AI technologies to transform physicians' clinical and administrative workflows. 

Key Points: 
  • The generative AI assistant allows physicians to understand their patients' health status, handle administrative requests, and get recommendations for care using the natural language of primary care.
  • "Navina's AI assistant is another step towards enhancing patient care by reducing the burden of documentation and time behind the screen for physicians."
  • The AI assistant is the only generative AI tool purpose-built for primary care that provides instant, concise responses based on multiple sources, including the EHR, health information exchange (HIE), claims data, and scanned documents.
  • "Navina has been pioneering a transformation in primary care for the last few years, and we are excited to see them bring their extensive experience to implementing innovative generative AI."